UT Health San Antonio-led research discovers how to slow or block recurrence of glioblastoma

Mayo Clinic researchers identify personalized approach to brain cancer monitoring

Mayo Clinic researchers have identified a potential new way to monitor the progression of high-grade gliomas, one of the most aggressive types of brain cancer.

April 25, 2025

Vol.51 No.16

Drugs & Targets

FDA grants Breakthrough Therapy designation for B7-H3 CAR T-cell therapy for diffuse intrinsic pontine glioma

BrainChild Bio Inc. announced that its investigational B7-H3 targeting autologous CAR T-cell therapy has been granted Breakthrough Therapy designation by FDA for the treatment of diffuse intrinsic pontine glioma, an incurable pediatric brain tumor.

April 25, 2025

Vol.51 No.16

In Brief

Michael Chan named chair of Wake Forest’s Department of Radiation Oncology

Michael Chan was appointed chair of Wake Forest University’s Department of Radiation Oncology, which he has led as interim chair since 2023. In his permanent role, he will advance the clinical, research and education missions of the department, while optimizing care delivery and clinical operations.

March 28, 2025

Vol.51 No.12

In Brief

Walter Curran, Jr. named Whitaker Endowed Chief of Piedmont Oncology

Walter J. “Wally” Curran, Jr. has been named the Whitaker Endowed Chief of Piedmont Oncology. This bestowed title is supported by the Piedmont Foundation’s Whitaker Endowment, a fund created by the Atlanta community in tribute to Piedmont’s cancer surgical leader, William Whitaker.

March 28, 2025

Vol.51 No.12

Clinical Roundup

Even light daily physical activity linked to lower cancer risk, NIH and Oxford study shows

In a prospective cohort study of more than 85,000 adults in the UK, researchers at the NIH and University of Oxford found that individuals who engaged in light- and moderate-to-vigorous-intensity daily physical activity had a lower risk of cancer than individuals who were more sedentary.

March 28, 2025

Vol.51 No.12

Clinical Roundup

Mutated cells can persist for years without becoming cancer and need an inflammatory “push” for malignancy to occur, COH study shows

Researchers at City of Hope have found that cell mutations are necessary but not always sufficient for tumors to form. Instead, they suggest that additional risk factors that promote tumor growth, like chronic inflammation, are a key trigger for tumor formation.

March 28, 2025

Vol.51 No.12

UT Health San Antonio-led research discovers how to slow or block recurrence of glioblastoma

YOU MAY BE INTERESTED IN

Mayo Clinic researchers identify personalized approach to brain cancer monitoring

FDA grants Breakthrough Therapy designation for B7-H3 CAR T-cell therapy for diffuse intrinsic pontine glioma

Michael Chan named chair of Wake Forest’s Department of Radiation Oncology

Walter Curran, Jr. named Whitaker Endowed Chief of Piedmont Oncology

Even light daily physical activity linked to lower cancer risk, NIH and Oxford study shows

Mutated cells can persist for years without becoming cancer and need an inflammatory “push” for malignancy to occur, COH study shows

Renew today!

Subscriber content

Never miss an issue!

Login